Table 2. Tumor pathology and IHC test results between the primary operation group and NAC group.
| NAC group (n = 152) | NAC group (n = 152) | NAC group (n = 152) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| CNB, No. (%) | SS, No. (%) | p-value | CNB, No. (%) | SS, No. (%) | p-value | CNB, No. (%) | SS, No. (%) | p-value | |
| Histology | 0.001 | < 0.001 | < 0.001 | ||||||
| IDC | 1,177 (85.8) | 1,208 (89.3) | 1,036 (85.0) | 1,099 (90.2) | 141 (92.8) | 109 (82.0) | |||
| ILC | 70 (5.1) | 59 (4.4) | 65 (5.3) | 58 (4.8) | 5 (3.3) | 1 (0.8) | |||
| CIN | 55 (4.0) | 22 (1.6) | 53 (4.3) | 5 (0.4) | 2 (1.3) | 17 (12.8) | |||
| Other | 69 (5.0) | 63 (4.7) | 65 (5.3) | 57 (4.7) | 4 (2.6) | 6 (4.5) | |||
| ER | 0.663 | 0.884 | 0.983 | ||||||
| Positive | 1,069 (78.0) | 1,058 (78.7) | 989 (81.1) | 991 (81.4) | 80 (52.6) | 67 (52.8) | |||
| Negative | 302 (22.0) | 287 (21.3) | 230 (18.9) | 227 (18.6) | 72 (47.4) | 60 (47.2) | |||
| PR | 0.980 | 0.903 | 0.193 | ||||||
| Positive | 928 (67.7) | 911 (67.7) | 870 (71.4) | 872 (71.6) | 58 (38.2) | 39 (30.7) | |||
| Negative | 443 (32.3) | 434 (32.3) | 349 (28.6) | 346 (28.4) | 94 (61.8) | 88 (69.3) | |||
| HER2 (IHC) | < 0.001 | < 0.001 | 0.248 | ||||||
| Negative | 1,005 (73.3) | 869 (64.6) | 910 (74.7) | 797 (65.4) | 95 (62.5) | 72 (56.7) | |||
| Positive | 232 (16.9) | 228 (17.0) | 190 (15.6) | 194 (15.9) | 42 (27.6) | 34 (26.8) | |||
| Equivocal | 134 (9.8) | 248 (18.4) | 119 (9.8) | 227 (18.6) | 15 (9.9) | 21 (16.5) | |||
| HER2 (IHC+SISH) | < 0.001 | < 0.001 | 0.146 | ||||||
| Negative | 1,011 (73.7) | 1,016 (75.5) | 910 (74.7) | 939 (77.1) | 101 (66.4) | 77 (60.6) | |||
| Positive | 236 (17.2) | 293 (21.8) | 190 (15.6) | 254 (20.9) | 46 (30.3) | 39 (30.7) | |||
| Equivocal | 124 (9.0) | 36 (2.7) | 119 (9.8) | 25 (2.1) | 5 (3.3) | 11 (8.7) | |||
| Ki-67 | 0.471 | 0.081 | < 0.001 | ||||||
| Low | 838 (61.5) | 845 (62.8) | 813 (67.1) | 776 (63.7) | 25 (16.6) | 69 (54.3) | |||
| High | 525 (38.5) | 500 (37.2) | 399 (32.9) | 442 (36.3) | 126 (83.4) | 58 (45.7) | |||
IHC=immunohistochemistry; NAC=neoadjuvant chemotherapy; CNB=core needle biopsy; SS=surgical specimens; IDC=invasive ductal carcinoma; ILC=invasive lobular carcinoma; CIN=carcinoma in situ; ER=estrogen receptor; PR=progesterone receptor; HER2=human epidermal growth factor receptor 2; SISH=silver in situ hybridization.